CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
29 Maio 2024 - 9:05AM
Business Wire
CareDx Reiterates Position that it Does Not
Infringe Natera’s ‘544 Patent
Injunction Motion has No Impact on CareDx’s
Business or Patient and Clinician Access to AlloSure or AlloMap
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on
the discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers – today responded to Natera, Inc.’s filing
of a motion for an injunction related to patent 11,111,544 (the
‘544 patent).
The motion seeks to stop CareDx from using a prior AlloSure®
process that Natera alleged infringed the ‘544 patent. That process
is no longer in effect. As CareDx informed Natera and the Court,
since August 2023, CareDx has utilized a new AlloSure process that
it believes does not infringe on the ‘544 patent.
The underlying validity of the ‘544 patent also remains subject
to judicial review.
“We believe the motion against a process that is no longer in
effect is irrelevant, and the District Court is still considering
the fundamental question of the validity of the ‘544 patent,” said
John W. Hanna, CareDx President and CEO. “We greatly appreciate the
continued support of the transplant community as we seek to resolve
these matters, allowing us to return our full attention to serving
patients and developing clinical innovations that improve
transplant care.”
Natera has previously claimed infringement on three patents:
- Prior to trial, the District Court dismissed patent 10,597,724
(the ‘724 patent) as invalid as patent ineligible.
- At trial, CareDx was found not to have infringed on patent
10,655,180 (the ‘180 patent).
- The ‘544 patent is the subject of post-trial motion practice in
which, among other things, CareDx is seeking to invalidate that
patent on the same grounds as the ‘724 patent.
Natera’s motion does not impact CareDx’s business or ability to
continue providing transplant patients with AlloSure or
AlloMap®.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward-Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the injunction
motion brought by Natera, the impact of the verdict on CareDx, and
CareDx’s motion seeking judicial review of the January 2024 jury
verdict including the validity of the ‘544 patent. These
forward-looking statements are based upon information that is
currently available to CareDx and its current expectations, speak
only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including risks that the impact of the
verdict differs from CareDx’s estimates; general economic and
market factors; and other risks discussed in CareDx’s filings with
the Securities and Exchange Commission (the “SEC”), including, but
not limited to, the Annual Report on Form 10-K for the fiscal year
ended December 31, 2023 filed by CareDx with the SEC on February
28, 2024, the quarterly report on Form 10-Q for the quarter ended
March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and
other reports that CareDx has filed with the SEC. Any of these may
cause CareDx’s actual results, performance, or achievements to
differ materially and adversely from those anticipated or implied
by CareDx’s forward-looking statements. CareDx expressly disclaims
any obligation, except as required by law, or undertaking to update
or revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529194946/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
CareDx (NASDAQ:CDNA)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025